2021
Threshold dose for intravenous nicotine self-administration in young adult non-dependent smokers
MacLean RR, DeVito EE, Eid T, Parida S, Gueorguieva R, Sofuoglu M. Threshold dose for intravenous nicotine self-administration in young adult non-dependent smokers. Psychopharmacology 2021, 238: 2083-2090. PMID: 33796907, PMCID: PMC8715498, DOI: 10.1007/s00213-021-05833-8.Peer-Reviewed Original ResearchConceptsDose of nicotineNicotine reinforcementHigh doseSubjective effectsHuman laboratory studiesYoung adult smokersNicotine self-administration modelNon-dependent smokersOvernight nicotine abstinenceEffects modelSelf-administration modelSelf-administration procedureNicotine doseAdult smokersMethodsYoung adultsObjectivesThe current studyNicotine abstinenceNicotine addictionHigh dosesLow dosesPlaceboThreshold doseReinforcement thresholdTobacco productsDose
2019
Double‐Blind Placebo‐Controlled Trial of Galantamine for Methadone‐Maintained Individuals With Cocaine Use Disorder: Secondary Analysis of Effects on Illicit Opioid Use
Carroll KM, DeVito EE, Yip SW, Nich C, Sofuoglu M. Double‐Blind Placebo‐Controlled Trial of Galantamine for Methadone‐Maintained Individuals With Cocaine Use Disorder: Secondary Analysis of Effects on Illicit Opioid Use. American Journal On Addictions 2019, 28: 238-245. PMID: 31165574, PMCID: PMC9078084, DOI: 10.1111/ajad.12904.Peer-Reviewed Original ResearchConceptsMethadone-maintained individualsOpioid useSecondary analysisMultiple drugsConcurrent cocaine dependenceTrial of galantaminePlacebo-controlled trialDouble-blind placeboIllicit opioid useRandomized clinical trialsCocaine use disorderGalantamine's effectFuture trialsClinical trialsUrine specimenUrine specimensUse disordersOpioidsCholinesterase inhibitorsMaintenance settingCocaine useCocaine dependencePlaceboConcurrent useGalantamineModulation of “Protective” Nicotine Perception and Use Profile by Flavorants: Preliminary Findings in E-cigarettes
DeVito EE, Jensen KP, O’Malley S, Gueorguieva R, Krishnan-Sarin S, Valentine G, Jatlow PI, Sofuoglu M. Modulation of “Protective” Nicotine Perception and Use Profile by Flavorants: Preliminary Findings in E-cigarettes. Nicotine & Tobacco Research 2019, 22: 771-781. PMID: 30995302, PMCID: PMC7368338, DOI: 10.1093/ntr/ntz057.Peer-Reviewed Original ResearchConceptsSubjective drug effectsNicotine-containing e-liquidsSelf-administered more nicotineAversive effectsSingle testing dayE-cigarettesSelf-reported preferencesE-cigarette appealRs16969968 genotypePreliminary findingsUnflavored e-liquidsIndividual differencesDrug effectsAd libitumE-liquidsAversive actionsTobacco productsNicotine effectsLow-risk groupNicotine-free e-liquidsPalatable flavorAversivenessTesting daysNicotinic acetylcholine receptor subunit genesNumber of puffs
2018
Acute effects of inhaled menthol on the rewarding effects of intravenous nicotine in smokers
Valentine GW, DeVito EE, Jatlow PI, Gueorguieva R, Sofuoglu M. Acute effects of inhaled menthol on the rewarding effects of intravenous nicotine in smokers. Journal Of Psychopharmacology 2018, 32: 986-994. PMID: 29788802, PMCID: PMC6329876, DOI: 10.1177/0269881118773972.Peer-Reviewed Original ResearchConceptsPositive subjective effectsPositive subjective responsesIntravenous nicotineNicotine metabolismSubjective effectsNicotine metabolite ratioYoung adult smokersSlower nicotine metabolismTest sessionsSubjective responsesSevere nicotine withdrawalMenthol inhalationNicotine withdrawalAcute effectsAdult smokersWithdrawal severityNicotine infusionRewarding effectsSmokersSmoking urgesChronic exposureMetabolite ratiosAversive effectsMenthol conditionsElectronic cigarettes
2013
Subjective, Physiological, and Cognitive Responses to Intravenous Nicotine: Effects of Sex and Menstrual Cycle Phase
DeVito EE, Herman AI, Waters AJ, Valentine GW, Sofuoglu M. Subjective, Physiological, and Cognitive Responses to Intravenous Nicotine: Effects of Sex and Menstrual Cycle Phase. Neuropsychopharmacology 2013, 39: 1431-1440. PMID: 24345818, PMCID: PMC3988546, DOI: 10.1038/npp.2013.339.Peer-Reviewed Original ResearchConceptsSubjective drug effectsMenstrual cycle phaseDrug effectsNicotine dependenceMenstrual cycle phase effectsFollicular phase womenSerious public health concernCycle phase effectsSymptoms of withdrawalLuteal phase femalesPublic health concernMenstrual phase differencesNicotine administrationOptimal treatmentIntravenous nicotineLuteal phaseOvernight abstinenceSmoking behaviorCycle phaseNicotine responseGreater physiological responsesBiochemical confirmationHealth concernEffects of sexBetter cognitionGender differences in a clinical trial for prescription opioid dependence
McHugh RK, DeVito EE, Dodd D, Carroll KM, Potter JS, Greenfield SF, Connery HS, Weiss RD. Gender differences in a clinical trial for prescription opioid dependence. Journal Of Substance Use And Addiction Treatment 2013, 45: 38-43. PMID: 23313145, PMCID: PMC3626739, DOI: 10.1016/j.jsat.2012.12.007.Peer-Reviewed Original ResearchConceptsPrescription opioid dependenceOpioid dependenceClinical trialsOpioid dependence severityPrescription drug dependenceLarge clinical trialsOpioid use outcomesGreater functional impairmentRoute of administrationSubstance use disordersGender differencesGreater psychiatric severityClinical characteristicsMedication doseStudy treatmentOpioid outcomesFunctional impairmentTreatment outcomesPre-treatment differencesPsychiatric severityTreatment retentionUse disordersLegitimate prescriptionDrug dependenceOpioids
2012
Memantine, an NMDA receptor antagonist, differentially influences Go/No-Go performance and fMRI activity in individuals with and without a family history of alcoholism
Jamadar S, DeVito EE, Jiantonio RE, Meda SA, Stevens MC, Potenza MN, Krystal JH, Pearlson GD. Memantine, an NMDA receptor antagonist, differentially influences Go/No-Go performance and fMRI activity in individuals with and without a family history of alcoholism. Psychopharmacology 2012, 222: 129-140. PMID: 22311382, PMCID: PMC3674025, DOI: 10.1007/s00213-011-2628-2.Peer-Reviewed Original ResearchConceptsNMDA receptor antagonistFamily historyFHN subjectsReceptor antagonistFHP subjectsN-methyl-D-aspartate receptor functionReceptor functionIdentical-appearing placeboEffects of memantineFMRI activityNMDA receptor functionCorrect rejectsSingle doseMemantineGo/No-Go taskSeparate daysTemporal regionsCingulate activation
2011
A preliminary study of the neural effects of behavioral therapy for substance use disorders
DeVito EE, Worhunsky PD, Carroll KM, Rounsaville BJ, Kober H, Potenza MN. A preliminary study of the neural effects of behavioral therapy for substance use disorders. Drug And Alcohol Dependence 2011, 122: 228-235. PMID: 22041256, PMCID: PMC3296894, DOI: 10.1016/j.drugalcdep.2011.10.002.Peer-Reviewed Original ResearchConceptsComputer-assisted cognitive behavioral therapyBehavioral therapySubstance use disordersInferior frontal gyrusCognitive behavioral therapyMaintenance of addictionUse disordersSubstance use outcomesCognitive controlFrontal gyrusTest-retest conditionsNeural effectsComponent of treatmentAnterior cingulateImpulse controlNeural systemsSame taskUse outcomesBOLD signalSubstance useSubstance abuseStroopComparison groupRandomized clinical trialsHealthy controls
2008
Methylphenidate improves response inhibition but not reflection–impulsivity in children with attention deficit hyperactivity disorder (ADHD)
DeVito EE, Blackwell AD, Clark L, Kent L, Dezsery AM, Turner DC, Aitken MR, Sahakian BJ. Methylphenidate improves response inhibition but not reflection–impulsivity in children with attention deficit hyperactivity disorder (ADHD). Psychopharmacology 2008, 202: 531. PMID: 18818905, PMCID: PMC2704617, DOI: 10.1007/s00213-008-1337-y.Peer-Reviewed Original ResearchConceptsAttention deficit hyperactivity disorderInformation Sampling TaskResponse inhibitionDeficit hyperactivity disorderHyperactivity disorderEducation-matched control groupPerformance of childrenForms of impulsivityStop-signal taskMeasures of impulsivityEffects of methylphenidateMulti-factorial constructADHD groupSignal taskImpulsivityPoor decisionsBehavioral symptomsMethylphenidateSampling tasksSame measuresPlacebo-controlled trialTaskChildrenImpairmentMeasuresThe Effects of Methylphenidate on Decision Making in Attention-Deficit/Hyperactivity Disorder
DeVito EE, Blackwell AD, Kent L, Ersche KD, Clark L, Salmond CH, Dezsery AM, Sahakian BJ. The Effects of Methylphenidate on Decision Making in Attention-Deficit/Hyperactivity Disorder. Biological Psychiatry 2008, 64: 636-639. PMID: 18504036, PMCID: PMC2577132, DOI: 10.1016/j.biopsych.2008.04.017.Peer-Reviewed Original ResearchConceptsAttention-deficit/hyperactivity disorderCambridge Gamble TaskADHD groupHyperactivity disorderDecision-making cognitionDecision-making deficitsEffects of methylphenidatePoor decision makingParent-reported symptomsHealthy age-matched control groupNeuropsychological markersEveryday behaviorStimulant medicationDisruptive behaviorPoor decisionsPoor judgmentBetting behaviorLittle empirical dataControl subjectsPlacebo sessionAge-matched control groupTaskDecision makingMethylphenidatePlacebo-controlled trial